Construction of infectious cDNA clones for dengue 2 virus: Strain 16681 and its attenuated vaccine derivative, strain PDK-53

Virology

Volumn 230, Issue 2, 1997, Pages 300-308

  Kinney, Richard M ^a   Butrapet, Siritorn ^b   Chang, Gwong Jen J ^a   Tsuchiya, Kiyotaka R ^a   Roehrig, John T ^a   Bhamarapravati, Natth ^b   Gubler, Duane J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTENUATION; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 2;

EID: 0030996972     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8500     Document Type: Article

References (44)

1. Arias C. F., Preugschat F., Strauss J. H. Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain. Virology. 193:1993;888-899.
2. Barrett A. D. T., Dunster L. M., Ledger T. N., Gibson C. A., Sil B. K., Sanders P. G., Gould E. A., Minor P. D. Evidence that the envelope protein of flaviviruses encodes determinants of attenuation and virulence. Vaccines 90. 1990;Cold Spring Harbor Laboratory Press, New York. p. 101-104.
3. Bhamarapravati N., Yoksan S. Study of bivalent dengue vaccine in volunteers. Lancet. 1:1989;1077.
4. Bhamarapravati N., Yoksan S. The clinical trial of trivalent dengue vaccine. Southeast Asian J. Trop. Med. Public Health. 21:1990;709.
5. Bhamarapravati N., Yoksan S., Chayaniyayothin T., Angsubphakorn S., Bunyaratvej A. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): Clinical, immunological and biological responses in adult volunteers. Bull. WHO. 65:1987;189-195.
6. Birnboim H. C., Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7:1979;1513-1523.
7. Blok J., McWilliam M., Butler H. C., Gibbs A. J., Weiller G., Herring B. L., Hemsley A. C., Aaskov J. G., Yoksan S., Bhamarapravati N. Comparison of a dengue-2 virus and its candidate vaccine derivative: Sequence relationships with the flaviviruses and other viruses. Virology. 187:1992;573-590.
8. Bray M., Lai C.-J. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. USA. 88:1991;10342-10346.
9. Bray M., Men R., Lai C.-J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70:1996;4162-4166.
10. Cahour A., Pletnev A., Vazeille-Falcoz M., Rosen L., Lai C.-J. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology. 207:1995;68-76.
11. Chambers T. J., Grakoui A., Rice C. M. Processing of the yellow fever virus nonstructural polyprotein: A catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites. J. Virol. 65:1991;6042-6050.
12. Chang G.-J. J., Cropp B. C., Kinney R. M., Trent D. W., Gubler D. J. Nucleotide sequence variation of the envelope protein gene identifies two distinct genotypes of yellow fever virus. J. Virol. 69:1995;5773-5780.
13. Chen W., Kawano H., Men R., Clark D., Lai C.-J. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J. Virol. 69:1995;5186-5190.
14. Coia G., Parker M. D., Speight G., Byrne M. E., Westaway E. G. Nucleotide and complete amino acid sequences of Kunjin virus: Definitive gene order and characteristics of the virus-specified proteins. J. Gen. Virol. 69:1988;1-21.
15. Dower W. J., Miller J. F., Ragsdale C. W. High efficiency transformation ofE. coli. Nucleic Acids Res. 16:1988;6127-6145.
16. Evans D. M. A., Dunn G., Minor P. D., Schild G. C., Cann A. J., Stanway G., Almond J. W., Currey K., Maizel J. V. Jr. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature. 314:1985;548-550.
17. Gorbalenya A. E., Donchenko A. P., Koonin E. V., Blinov V. M. N-terminal domains of putative helicases of flavi and pestiviruses may be serine proteases. Nucleic Acids Res. 17:1989a;3889-3897.
18. Gorbalenya A., Koonin E. V., Donchenko A. P., Blinov V. M. Two related superfamilies of putative helicases involved in replication, recombination, repair and expression of DNA and RNA genomes. Nucleic Acids Res. 17:1989b;4713-4730.
19. Gubler D. J. Application of serotype-specific monoclonal antibodies for identification of dengue viruses. Yunker C. Arboviruses in Arthropod Cellsin Vitro. 1987;3-14 CRC Press, Boca Raton.
20. Halstead S. B., Simasthien P. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J. Biol. Med. 42:1970;276-292.
21. Halstead S. B., Udomsakdi S., Simasthien P., Singharaj P., Sukhavachana P., Nisalak A. Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses. Yale J. Biol. Med. 42:1970;261-275.
22. Henchal E. A., McCown J. M., Burke D. S., Seguin M. C., Brandt W. E. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34:1985;162-169.
23. Khin M. M., Jirakanjanakit N., Yoksan S., Bhamarapravati N. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 51:1994;864-869.
24. Kinney R. M., Chang G.-J., Tsuchiya K. R., Sneider J. M., Roehrig J. T., Woodward T. M., Trent D. W. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5′-noncoding region and the E2 envelope glycoprotein. J. Virol. 67:1993;1269-1277.
25. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
26. Lewis J. A., Chang G.-J., Lanciotti R. S., Trent D. W. Direct sequencing of large flavivirus PCR products for analysis of genome variation and molecular epidemiological investigations. J. Virol. Methods. 38:1992;11-24.
27. Liljeström P., Lusa S., Huylebroeck D., Garoff H. In vitro. J. Virol. 65:1991;4107-4113.
28. Macadam A. J., Stone D. M., Almond J. W., Minor P. D. The 5′ noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol. 2:1994;449-454.
29. Milligan J. F., Groebe D. R., Witherell G. W., Uhlenbeck O. C. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. 15:1987;8783-8798.
30. Obijeski J. F., Bishop D. H. L., Murphy F. A., Palmer E. L. Structural proteins of La Crosse virus. J. Virol. 19:1976;985-997.
31. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B. L., Kameda A., Itoh H., Arita M., Wimmer E., Nomoto A. Genetic analysis of the attenuation phenotype of poliovirus type 1. J. Virol. 58:1986;348-358.
32. Pause A., Sonenberg N. Mutational analysis of a DEAD box RNA helicase: The mammalian translation initiation factor elF-4A. EMBO J. 11:1992;2643-2654.
33. Rice C. M., Grakoui A., Galler R., Chambers T. J. Transcription of infectious yellow fever RNA from full-length cDNA templates produced byin vitro. New Biol. 1:1989;285-296.
34. Rice C. M., Lenches E. M., Eddy S. R., Shin S. J., Sheets R. L., Strauss J. H. Nucleotide sequence of yellow fever virus: Implications for flavivirus gene expression and evolution. Science. 229:1985;726-735.
35. Riggs J. L. Immunofluorescent staining. Lennette E. H., Schmidt N. J. Diagnostic Procedures for Viral, Rickettsia, and Chlamydial Infections," 5th ed. 1979.
36. Roehrig J. T., Mathews J. H., Trent D. W. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology. 128:1983;118-126.
37. Sambrook J., Fritsch E. F., Maniatis T. Molecular Cloning: A Laboratory Manual. 1989;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
38. Speight G., Westaway G. Positive identification of NS4A, the last of the hypothetical nonstructural proteins of flaviviruses. Virology. 170:1989;299-301.
39. Vaughn D. W., Hoke C. H. Jr., Yoksan S., LaChances R., Innis B. L., Rice R. M., Bhamarapravati N. Testing of a dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in ten American volunteers. Vaccine. 14:1996;329-336.
40. Warrener P., Tamura J. K., Collett M. S. RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria. J. Virol. 67:1993;989-996.
41. Wengler G., Wengler G. The carboxy-terminal part of the NS3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology. 184:1991;707-715.
42. Wengler G., Czaya G., Färber P. M., Hegemann J. H. In vitro. J. Gen. Virol. 72:1991;851-858.
43. Westaway E. G., Brinton M. A., Gaidamovich S. Ya., Horzinek M. C., Igarashi A., Kääriänen L., Lvov D. K., Porterfield J. S., Russell P. K., Trent D. W. Flaviviridae. Intervirology. 74:1985;183-192.
44. S. Yoksan, N. Bhamarapravati, S. B. Halstead, 1986, Dengue virus vaccine development: Study on biological markers of uncloned dengue 1-4 viruses serially passaged in primary kidney cells, Arbovirus Research in Australia, Proceedings of the Fourth Symposium, T. D. St. GeorgeB. H. KayJ. Blok, 35, 38, CSIRO/QIMR, Brisbane.